_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.jpg "James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 33 sec
✓ Published: 28-Jan-2018
✓ Published: 28-Jan-2018
Description:
James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_an-overview-of-parp-inhibitors-in-ovarian-cancer.webp "Targeted Oncology")
_parp-inhibitors-for-ovarian-cancer.webp "VJOncology")
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.webp "Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.")
_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023.webp "Touch Medical Media Services")
_ctsc-124-stenoparib-and-covid-19.webp "Stenoparib Publication in MBio JournalnnStenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 and HCoV-NL63 human coronaviruses in vitro.nnMore info: https://joinpmi.com/ctsc-stenoparib-and-covid-19")
_parp-inhibitors-in-combination-with-nhas.webp "In this GU CONNECT programme from Dr Andrew Armstrong, you'll follow a patient through their prostate cancer journey and explore the clinical implementation of genetic testing and PARP inhibitors in combination with novel hormonal agents (NHAs). It follows Dr Neal Shore's animated video exploring PARPis as monotherapy.nnWatch the animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testi")
_what-key-factors-impact-prostate-cancer-treatment-decisions.webp "Prostate cancer expert Dr. Channing Paller reviews key variables that impact prostate cancer treatment decisions and explains immunotherapy, PARP inhibitors, and personalized medicine.nnDr. Channing Paller is Director of Prostate Cancer Clinical Research at Johns Hopkins Medicine. Learn more about Dr. Paller here: https://www.hopkinsmedicine.org/profiles/details/channing-paller")
_2021-07-09-parp-i-for-non-hrd-population-dr-ryan-spencer-mp4.webp "2021-07-09 PARP-i for non-HRD population - Dr. Ryan Spencer.mp4 from parp")
_an-overview-of-parp-inhibitors-in-ovarian-cancer.jpg)
_parp-inhibitors-for-ovarian-cancer.jpg)
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.jpg)
_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023.jpg)
_ctsc-124-stenoparib-and-covid-19.jpg)
_parp-inhibitors-in-combination-with-nhas.jpg)
_what-key-factors-impact-prostate-cancer-treatment-decisions.jpg)
_2021-07-09-parp-i-for-non-hrd-population-dr-ryan-spencer-mp4.jpg)
![[+]](/images/menu.gif){kind=small}